Funding event
The round itself, as filedInferred stageSeries B
Sold of offered$49.8M of $57.5M
Filed2026-10-13
Days since filing31
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-09-18
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- John V. Frangioni, M.D., Ph.D.Executive Officer · Director
- Garen BohlinDirector
- Marc V. Garnick, M.D.Director
- Sean StalfortDirector
- Walid FakhryDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-11-13UndersubscribedNot flagged$49.8M of $57.5M sold1.8 months since first sale
Prior raiseNot flaggedRaised $49.8M against a prior $14.5M$14.5M prior raise, filed 2025-10-09
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-11-130
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
Also raised in Health & bio
Same sector, 28 days to 2026-11-15OrcosaSeries A · $6.0M of $11.5M · Ewing, NJQuietChronicleBioPre-seed · $250K of $1.0M · Menlo Park, CAQuiet
103 rounds in Health & bio in the 28 days to 2026-11-12, against 122 in the 28 days before.